Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12466MR)

This product GTTS-WQ12466MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000878.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3560
UniProt ID P14784
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ12466MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8440MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HspE7
GTTS-WQ2287MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ3490MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ5939MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ8210MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA hLIV22
GTTS-WQ3132MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ15409MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ1974MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS-15E
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW